Abivax to Unveil Phase 3 Obefazimod Results for Ulcerative Colitis at UEG 2025

Efficacy Data in Focus: UEG Late-Breaking Presentation Sheds Light on Obefazimod’s Phase 3 Trials

Abivax is preparing to showcase a late-breaking abstract highlighting eight-week data from its Phase 3 ABTECT induction trials of obefazimod for moderately to severely active ulcerative colitis at the United European Gastroenterology (UEG) Meeting in Berlin, taking place October 4–7, 2025. The findings—centered on patient subsets who previously showed inadequate responses to advanced therapies—promise to offer valuable insight for the GI and investment communities.

Targeted Insights: Addressing Patients with Unmet Need

The scheduled presentation, titled “Efficacy of Obefazimod in ABTECT Phase 3 Induction Trials: Results of 8-Week Therapy in Subsets of Patients With and Without Prior Inadequate Response to Advanced Therapies,” will be delivered by Dr. Silvio Danese on October 6 at 10:00 am CET. The session will spotlight both the efficacy and broader applicability of obefazimod, particularly for individuals who have failed to benefit from existing advanced treatments for ulcerative colitis.

Investor and Analyst Call Scheduled as Interest Builds Around Upcoming Data

In tandem with the scientific presentation, Abivax’s management will host an investor and analyst call at 3:00 pm CET (9:00 am ET) on October 6 to review and discuss the newly revealed Phase 3 data. This move signals confidence in obefazimod’s potential impact, not just within scientific circles but also for investors monitoring advances in immunology and gastrointestinal treatments.

Pipeline in Perspective: Broader Implications for Chronic Inflammatory Disease Therapies

Obefazimod, Abivax’s lead clinical-stage drug candidate, has garnered attention for its mechanism designed to modulate immune regulation in chronic inflammatory diseases. As it nears key regulatory milestones, these Phase 3 results will provide critical evidence of its promise as a future therapy for ulcerative colitis, especially for those patients underserved by current therapies.

Takeaway: What to Watch at UEG 2025

With late-breaking, peer-reviewed clinical results and focused sessions on new mechanisms in ulcerative colitis, Abivax’s presence at UEG 2025 underscores growing anticipation in the field. Whether these Phase 3 data position obefazimod as a transformative new option will depend on both clinical and investor response in the weeks to follow.

For additional information on event times, live streams, and participation, investors and clinicians can visit the UEG website or contact Abivax directly at their booth (#4.25 in Hall 4.2) in Berlin.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI